Grants to Licensee. Subject to Section 2.2 and the other terms and conditions of this Agreement, AstraZeneca hereby grants to Licensee:
Grants to Licensee. Subject to Section 2.2 and Section 4.7 and the other terms and conditions of this Agreement, Sanofi hereby grants to Licensee an exclusive (including with regard to Sanofi and its Affiliates) license (or sublicense), with the right to grant sublicenses in accordance with Section 2.3 or after Licensee complies with all of its obligations under Section 4.7, under the Licensed Patents and the Licensed Know-How to Exploit the Licensed Compound and Licensed Product in the Field in the Territory.
Grants to Licensee. Subject to Sections 3.7.3 and 5.3 and the other terms and conditions of this Agreement, Licensor (on behalf of itself and its Affiliates) hereby grants to Licensee:
Grants to Licensee. Medimmune hereby grants to Licensee:
Grants to Licensee. Subject to Section 2.3 and Section 2.4 and the other terms and conditions of this Agreement, MedImmune hereby grants to Licensee an exclusive (including with regard to MedImmune and its Affiliates) license, with the right to grant sublicenses in accordance with Section 2.3, under the Licensed Know-How, Licensed Patents, and MedImmune’s interest in Joint Inventions and Joint Patents, solely to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory and for no other purpose; provided, however, that the license granted to Licensee in this Section 2.1 shall include each Additional Compound solely to the extent that Licensee complies with Section 2.4.4 with respect to such Additional Compound and only for as long as such Additional Compound is not an Excluded Compound. *** CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Grants to Licensee. Subject to the terms and conditions of this Agreement and the applicable terms and conditions of the Spectrum Agreement, GPC Biotech (on behalf of itself and its Affiliates) hereby grants to Licensee:
Grants to Licensee. Subject to Section 2.4, Section 5.2.1, Section 5.2.2, and the other terms and conditions of this Agreement, AbbVie hereby grants to Licensee an exclusive (including with regard to AbbVie and its Affiliates) license, with the right to grant sublicenses in accordance with Section 2.2, under the AbbVie Know-How, AbbVie Patents and AbbVie’s interest in the Joint IP, to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory.
Grants to Licensee. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee:
Grants to Licensee. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee: 2.1.1 an exclusive (including with regard to Licensor and its Affiliates), royalty-bearing license, with the right to grant sublicenses in accordance with Section 2.3, under the Licensor Patents and the Licensor Know-How to Develop, to obtain, maintain and hold Regulatory Approvals for, and to Commercialize the Licensed Products in the Field in the Licensee Territory; 2.1.2 a non-exclusive royalty-free license, with the right to grant sublicenses in accordance with Section 2.3, under the Joint Patents (to the extent Controlled by Licensor) and the Joint Know-How (to the extent Controlled by Licensor) or any other Intellectual Property Rights Controlled by Licensor that relate to the Licensed Compound or the Licensed Products to Develop, to obtain, maintain and hold Regulatory Approvals for, and to Commercialize the Licensed Products in the Field in the Licensee Territory; 2.1.3 a royalty-bearing license, exclusive in the Licensee Territory, with the right to grant sublicenses in accordance with Section 2.3, to use the Product Trademarks as necessary to exercise its rights under the grants in Sections 2.1.1 and 2.1.2; 2.1.4 an exclusive royalty-bearing license and right of reference in the Licensee Territory, with the right to grant further sublicenses and rights of reference to Sublicensees in accordance with Section 2.3, under Licensor’s right, title and interest in and to any Clinical Data, Regulatory Approvals, Drug Master File and all Regulatory Documentation that Licensor may Control with respect to the Licensed Compound or the Licensed Products as necessary to exercise Licensee’s rights under the grants in Sections 2.1; 2.1.5 to the extent necessary to exercise Licensee’s rights under the grants in Section 2.1, Licensor hereby grants, and shall ensure that its Affiliates and Sublicensees grant, to Licensee and its Sublicensees a “right of reference or use” (as that term is defined in 21 C.F.R. §314.3(b), as amended from time to time), and any non-United States equivalents (including Article 10c of Directive 2001/83/EC, as amended), to any and all data contained or referenced in
Grants to Licensee. Subject to Sections 2.2, 2.5 and the other terms and conditions of this Agreement, RVL hereby grants to Licensee:
